<DOC>
	<DOCNO>NCT02189941</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic safety profile sustained-release formulation deferiprone fast feed condition , evaluate relative bioavailability sustained-release formulation compare immediate-release formulation deferiprone fast condition .</brief_summary>
	<brief_title>Pilot Study Pharmacokinetic Profile Deferiprone Sustained-Release Formulation Healthy Volunteers</brief_title>
	<detailed_description>This open-label , single-dose , randomize , three-way crossover study feed fasting condition design determine pharmacokinetics , safety , tolerability deferiprone sustained-release tablet healthy volunteer . Subjects randomize receive follow 3 treatment different order , washout period 7 day treatment : - 2000 mg deferiprone sustained-release tablet feed condition - 2000 mg deferiprone sustained-release tablet fast condition - 2000 mg Ferriprox immediate-release tablet fast condition In period , blood sample pharmacokinetics ( PK ) assessment collect prior dose specify time point 24 hour post-dose . Safety assessment conduct throughout study .</detailed_description>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main Meeting age , body mass index ( BMI ) weight requirement . Signing Informed Consent Form . Acceptable alcohol and/or drug screen checkin period . Acceptable health , blood pressure , pulse rate temperature checkin . Being nonsmoker . Female subject childbearing potential either sexually inactive ( abstinent ) 60 day prior first dose study throughout study , 30 day completion study , use acceptable method birth control . A history presence significant asthma , chronic bronchitis , seizure , diabetes , migraine , hypertension , cardiovascular , pulmonary , neurological condition , psychiatric condition , hepatic , renal , hematopoietic gastrointestinal disease ongoing infectious disease , significant abnormality evidence medical history physical examination . Blood chemistry , hematology , international normalize ratio , partial thromboplastin time urinalysis value outside clinically acceptable limit . A positive screen Hepatitis B surface antigen , Hepatitis C antibodies HIV . Significant abnormality find ECG . Known sensitivity deferiprone component Ferriprox tablet . Requiring medication time study . Oral , injectable topical contraceptive , contraceptive implant permit acceptable method contraception . Acetaminophen use within 2 week prior dose duration study . History drug alcohol abuse within last 6 month . Any known enzyme induce inhibit drug take within 30 day study . History long QT syndrome , cardiac arrhythmia . Infection within two week prior dose . Participation investigational drug study within 30 day prior first dose study . Blood donation 50 mL 499 mL whole blood within 30 day , 499 mL whole blood within 56 day prior drug administration . Positive test pregnancy medical screening prior dose either period . Female subject breastfeed . Absolute neutrophil count ( ANC ) &lt; = 1.0 x 10E9 cells/L prior dosing period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Deferiprone</keyword>
	<keyword>Deferiprone sustained-release tablet</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>